Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative nivolumab + ipilimumab in localized MSI/dMMR oeso-gastric adenocarcinoma
2018-004712-22Phase 2Completed
- Sponsor
- GERCOR
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and cancer, sponsored by GERCOR. Primary endpoint: Complete pathological response rate. Started Apr 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomacancer
Beyond the preview
Go deeper on 2018-004712-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004712-22.